Eisai Co Ltd (4523.T)
23 Oct 2018
(This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970)
CORRECTED-(OFFICIAL)-UPDATE 2-Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)
* Wholesale price before discount is $16,970 for a 30-day supply
Aug 16 The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.
TOKYO, July 26 Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)
CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.
Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose. | Video
* Eisai shares up as much as 14.6 pct in morning Tokyo trading
July 5 Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.